Yahoo · Sep 1, 2026
MiniMed submits new patch pump for FDA clearance
The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.
TN
NASDAQ · TNDM
Tandem Diabetes Care, Inc.
Healthcare · Medical - Devices
$19.11
Down-$0.80 (-4.19%)
Updated Sep 10, 2026, 11:02 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.42B
- P/E ratio
- -6.98
- Dividend yield
- 0.00%
- 52-week range
- $11.46 – $29.65
- Volume
- 1.57M
- Avg. volume
- 2.11M
Price performance
TNDM price history
1M range · 20 trading sessions · Daily adjusted prices
TNDM closed at $19.11 after 20 trading sessions, down 18.47% for the selected period.
- Last close
- $19.11
- Period change
- -18.47%
- Period low
- $19.11
- Period high
- $23.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $19.67 | $19.73 | $19.035 | $19.11 | 1.57M |
| Sep 8, 2026 | $19.51 | $20.62 | $19.34 | $19.88 | 1.64M |
| Sep 4, 2026 | $20.04 | $20.36 | $19.49 | $19.90 | 1.36M |
| Sep 3, 2026 | $20.71 | $20.91 | $20.03 | $20.43 | 1.59M |
| Sep 2, 2026 | $21.25 | $21.735 | $20.54 | $20.56 | 1.14M |
| Sep 1, 2026 | $21.98 | $22.2105 | $21.08 | $21.28 | 919.28K |
| Aug 31, 2026 | $21.00 | $22.295 | $20.56 | $22.01 | 1.66M |
| Aug 28, 2026 | $21.40 | $21.77 | $21.22 | $21.43 | 921.99K |
| Aug 27, 2026 | $21.20 | $21.94 | $21.02 | $21.40 | 1.03M |
| Aug 26, 2026 | $21.24 | $21.585 | $21.02 | $21.37 | 1.12M |
| Aug 25, 2026 | $22.16 | $22.16 | $21.30 | $21.58 | 1.19M |
| Aug 24, 2026 | $22.40 | $23.00 | $22.06 | $22.22 | 1.06M |
| Aug 21, 2026 | $23.25 | $23.25 | $22.06 | $22.32 | 1.64M |
| Aug 20, 2026 | $23.11 | $23.53 | $22.22 | $22.57 | 1.82M |
| Aug 19, 2026 | $24.20 | $24.81 | $23.42 | $23.46 | 1.66M |
| Aug 18, 2026 | $22.16 | $24.10 | $22.097 | $23.73 | 2.63M |
| Aug 17, 2026 | $22.50 | $22.94 | $21.70 | $22.255 | 1.38M |
| Aug 14, 2026 | $22.92 | $22.92 | $22.355 | $22.72 | 1.69M |
| Aug 13, 2026 | $23.33 | $23.555 | $22.88 | $23.13 | 1.42M |
| Aug 12, 2026 | $23.16 | $23.605 | $22.71 | $23.44 | 1.7M |
Latest TNDM news
The latest Smart Investors Daily articles mentioning TNDM.
Stock researchCompany · Overview
TNDM research
Overview
Company profile and research snapshot.
Company profile
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | William Blair | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Citigroup | Neutral | — |
| Jul 15, 2026 | Mizuho | Neutral | — |
| Jun 23, 2026 | Deutsche Bank | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 31, 2026
Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
Yahoo · Aug 25, 2026
3 Reasons TNDM is Risky and 1 Stock to Buy Instead
Over the last six months, Tandem Diabetes’s shares have sunk to $22.45, producing a disappointing 13.7% loss - a stark contrast to the S&P 500’s 10.5% gain. This might have investors contemplating their next move.
Yahoo · Aug 25, 2026
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
